By imaging the tumor stroma rather than tumor cells, 68Ga-labeled FAP inhibitor (FAPI) PET/CT reveals elevated radioactivity on primary and metastatic lesions and low background uptake in normal tissues among various tumors, including gastrointestinal tumors (16), hepatobiliary tumors (17), and head and neck cancers (18). This evidence concerns the gene FAP and neoplasm.